Clinical Trial Update: ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 ASCERTAIN trial evaluating adding everolimus to a reduced calcineurin inhibitor regimen in renal transplant recipients; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Zortress (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2011-05-02